Scientific article
OA Policy
English

Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics

Published in

American Heart Journal, vol. 220, p. 203-212

Publication date

2020

Abstract

People living with human immunodeficiency virus (PLHIV) are at higher risk of atherosclerotic cardiovascular disease (ASCVD) due to traditional and HIV- or antiretroviral treatment (ART)-related risk factors. The use of high-intensity statin therapy is often limited by comorbidities and drug–drug interactions with ART. Herein, we present the design and baseline characteristics of the BEIJERINCK study, which will assess the safety and efficacy of evolocumab in PLHIV and hypercholesterolemia/mixed dyslipidemia.

UNIGE research groups

Citation (ISO format)

BOCCARA, Franck et al. Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics. In: American Heart Journal, 2020, vol. 220, p. 203–212. doi: 10.1016/j.ahj.2019.11.004

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

0002-8703
269views
164downloads

Technical informations

Creation

30/10/2020 20:21:00

First validation

30/10/2020 20:21:00

Update

16/03/2023 00:55:19

Status update

16/03/2023 00:55:17

Last indexation

31/10/2024 22:35:24
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated